Hákon Hákonarson (scientist)
Hakon Hakonarson | |
|---|---|
| Born | Iceland |
| Citizenship | Iceland, USA |
| Alma mater | University of Iceland |
| Known for | Founding Director of the Center for Applied Genomics; data-driven individualized medicine; genomics, ANNOVAR |
| Awards | 1995 Parker B. Francis Science Award, Parker B. Francis Foundation; 2002 Excellence in Science Award for Pediatric Research, University of Iceland; The 2009 Scripps Genomics Medicine Award: Pioneering Discoveries in Pediatric Genomics, Scripps Research, 2016 Inaugural CHOP Mentor Award; 2017 Children’s Hospital of Philadelphia Endowed Chair in Genomic Research |
| Scientific career | |
| Fields | Genomics, Bioinformatics, Pediatrics, Pulmonology, Individualized medicine, Translational medicine, Datamining |
| Institutions | Children's Hospital of Philadelphia; University of Pennsylvania |
Hakon Hakonarson, M.D., Ph.D. is Founding Director of the Center for Applied Genomics and Endowed Chair in Genomics Research at the Children’s Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is also an attending physician in pulmonary medicine. Hakonarson leads a major commitment from the Children’s Hospital of Philadelphia to genomically characterize over 100,000 children, an initiative that has resulted in the development of multiple novel rare disease therapies and international recognition.[1].
Impact
Hakonarson has published numerous papers on genomic discoveries and their translations in scientific medical journals, including Nature (journal), Nature Medicine, Nature Genetics, Cell (journal), Science (journal) and The New England Journal of Medicine. Time Magazine listed Dr. Hakonarson’s autism gene discovery project, reported in Nature in 2009, among the top 10 medical breakthroughs of that year[2]. Dr. Hakonarson’s Nature Medicine paper on a novel precision based therapy in rare lymphatic disorders was awarded among the Top 10 clinical/translational papers in 2019 by the Clinical Research Forum[3].
Work by Hakonarson involving complex lymphatic disorders is representative of work originating from genetic discoveries and then advancing through translational research and modeling studies and qualifying for clinical/translational opportunities[4].
Hakonarson’s NFC-1 program addressing mGluR signaling in a subset of patients with ADHD and autism, was acquired by Medgenics Inc. in 2015[5], following a successful proof-of-concept study based on genetic stratification.
References
- ^ "Hakon Hakonarson - Google Scholar Citations". scholar.google.com.
- ^ "Time Magazine, Top 10 of Everything: Medical Breakthroughs".
- ^ "Clinical Research Forum: Top 10 Clinical Research Achievement Awards - Top 10 Awardees".
- ^ "CHOP Researchers Reverse Severe Lymphatic Disorder in Patient with Noonan Syndrome by Targeting Genetic Pathway".
- ^ "MDGN: neuroFix Acquisition Could Be A Needle-Mover, September 11, 2015".